Global Aspergillosis Market to Reach USD 5.15 Billion by 2030 as Advanced Diagnostics and Antifungal Therapies Drive Growth

Global Aspergillosis Market Overview

The Global Aspergillosis Market is witnessing steady growth as healthcare systems focus on the diagnosis, treatment, and management of fungal infections caused by Aspergillus. According to Maximize Market Research, the market was valued at USD 3.99 billion in 2023 and is expected to reach nearly USD 5.15 billion by 2030, expanding at a CAGR of 3.7% from 2024 to 2030. Rising prevalence among immunocompromised populations, improvements in diagnostic capabilities, and continuing development of antifungal therapies are key factors supporting market expansion.

Aspergillosis can range from allergic conditions to severe invasive infections, creating demand for differentiated diagnostic and therapeutic approaches. Increasing numbers of patients undergoing transplantation, cancer treatment, intensive immunosuppressive therapy, and other procedures associated with weakened immunity are strengthening the need for effective disease management. Improved awareness among healthcare professionals and greater availability of specialized testing are also contributing to earlier detection.

The market presents significant opportunities through new antifungal formulations, rapid diagnostics, preventive strategies, and therapies designed to address drug resistance and treatment limitations. Research into targeted and inhaled antifungal treatments is particularly important because conventional systemic therapies can face challenges related to toxicity, drug interactions, and resistance. Pulmocide, for example, has been developing inhaled opelconazole to deliver high concentrations directly to the lungs while limiting systemic exposure.

* Request Your Free Sample Copy: https://www.maximizemarketresearch.com/request-sample/233535/ 

US Market Trends and Investment

The United States represents a major market for aspergillosis management, supported by advanced healthcare infrastructure, specialized infectious-disease centers, strong pharmaceutical research capabilities, and high awareness of fungal infections. In 2025, the American Thoracic Society published an official clinical practice guideline addressing treatment of invasive pulmonary aspergillosis, highlighting continued efforts to strengthen evidence-based diagnosis and treatment strategies. Meanwhile, drug-development activity continued to attract investment. Pulmocide presented its development program at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025, while its inhaled opelconazole program remained focused on difficult-to-treat pulmonary aspergillosis. Research into next-generation antifungal candidates is also progressing, with fosmanogepix being evaluated for invasive mold diseases caused by Aspergillus and rare molds. These developments demonstrate continued U.S. investment in improved antifungal options and disease-management technologies.

Market Segmentation

According to the supplied Maximize Market Research report, the market is segmented by Type, Drug Type, Route of Administration, End User, and Region. The type segment includes Invasive Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), and other less common types. Drug types include Isavuconazole, Voriconazole, Amphotericin-B, Itraconazole, Corticosteroids, Posaconazole, and Others. The market is further divided by oral and intravenous administration and by hospitals, ambulatory clinics, retail pharmacies, and other end users.

Among these categories, Invasive Aspergillosis held the largest share, accounting for approximately 70% of the global market in 2023. The segment is expected to continue growing at a 3.7% CAGR through the forecast period. Its dominance is associated with the serious nature of invasive disease and the need for intensive antifungal treatment among severely immunocompromised patients.

Aspergillosis Market Key Players
1. North America

1. Pulmonomy Associates Inc (United States)
2. Scynexis Inc (United States)
3. Pfizer Inc (United States)
4. TFF Pharmaceuticals Inc (United States)
5. Thermo Fisher Scientific (United States)
6. Merck & Co (United States)
7. Pulmatrix (United States)
8. Lupin Pharmaceuticals (United States)
9. Aozeal (California)
10. Xellia Pharmaceuticals (Denmark)
11. Mylan Pharmaceuticals (United States)
12. Abbott Laboratories (United States)
13. Eli Lilly and Company (United States)
14. Johnson & Johnson Services, Inc. (United States)

2. Europe

1. GlaxoSmithKline (United Kingdom)
2. AstraZeneca (United Kingdom)
3. Novartis AG (Switzerland)
4. Bayer AG (Germany)
5. Hikma Pharmaceuticals (United Kingdom)
6. F2G Ltd (United Kingdom)
7. Pulmocide Ltd (United Kingdom)
8. Basilea Pharmaceutica Ltd (Switzerland)
9. Biosergen AS (Norway)

3. Asia Pacific

1. Cellix Bio Pvt Ltd (India)
2. AbGenics Life Sciences Pvt Ltd (India)
3. Rewine Pharmaceuticals (Inida)
4. Eugia Pharma (India)
5. Krishlar Pharmaceuticals (India)
6. Cipla (India)
7. Astellas Pharma (Japan)
8. Mayne Pharma Group Limited (Australia)
9. Takeda Pharmaceutical Company Ltd (Japan)

4. Middle East & Africa

1. Teva Pharmaceuticals (Israel)

Competitive Analysis

The Maximize Market Research report identifies Pulmonomy Associates Inc., Scynexis Inc., Pfizer Inc., TFF Pharmaceuticals Inc., Thermo Fisher Scientific, Merck & Co., Pulmatrix, Lupin Pharmaceuticals, Aozeal, Xellia Pharmaceuticals, Mylan Pharmaceuticals, Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson Services, GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Hikma Pharmaceuticals, F2G, Pulmocide, Basilea, Biosergen, Astellas Pharma, Takeda Pharmaceutical, Cipla, and other companies in the competitive landscape. The report does not provide individual percentage shares for the five largest companies, so they cannot be ranked by exact market share without unsupported assumptions.

Pfizer remains an important participant in antifungal treatment and infectious-disease research. Its acquisition of Amplyx brought fosmanogepix into Pfizer's portfolio, supporting development of a novel antifungal mechanism for serious invasive fungal infections. Clinical research published in 2025 continued to evaluate fosmanogepix in invasive mold diseases, including infections caused by Aspergillus.

Merck & Co. is another major antifungal market participant, with established antifungal products and continuing involvement in research and development addressing invasive fungal infections. Its position in infectious diseases supports opportunities for further therapeutic innovation.

Gilead Sciences has an established role in antifungal treatment through its infectious-disease portfolio and continues to participate in clinical research surrounding invasive aspergillosis and next-generation antifungal therapies. Current clinical research shows Gilead among companies supporting studies and development activity in this field.

Astellas Pharma is identified by the MMR report as a key Asia Pacific participant and is also active in antifungal research. Its involvement in studies surrounding invasive aspergillosis and emerging therapies reinforces the company's role in advancing treatment options.

Pulmocide represents an innovative emerging participant. Its lead candidate, inhaled opelconazole, was designed specifically to target respiratory fungal infections while minimizing systemic exposure. The company had been advancing the therapy through late-stage development and received FDA orphan-drug, Fast Track, and QIDP designations.

Regional Analysis

United States: North America dominated the Global Aspergillosis Market with more than 40% share in 2023, according to Maximize Market Research. The region's advanced healthcare infrastructure, specialized treatment centers, diagnostic capabilities, and pharmaceutical R&D ecosystem support its leadership.

United Kingdom: The UK benefits from established infectious-disease research capabilities and pharmaceutical innovation. Companies such as GSK, F2G, and Pulmocide contribute to the regional competitive landscape identified by MMR.

Germany: Germany's advanced healthcare infrastructure, strong clinical research environment, and participation in European infectious-disease research provide opportunities for improved aspergillosis diagnosis and treatment.

France: France offers growth potential through specialized healthcare services, infectious-disease research, and increasing emphasis on accurate diagnosis of serious fungal infections.

Japan: Japan is an important Asia Pacific market, supported by its advanced pharmaceutical industry and companies such as Astellas and Takeda. Asia Pacific is identified by MMR as the fastest-growing regional market during the forecast period.

China: China's expanding healthcare infrastructure, large patient population, pharmaceutical manufacturing capabilities, and increasing access to advanced diagnostic technologies create long-term opportunities for the aspergillosis market.

Conclusion

The Global Aspergillosis Market, valued at USD 3.99 billion in 2023, is projected to reach USD 5.15 billion by 2030, growing at a 3.7% CAGR.

In my view, the strongest growth opportunity will come from combining earlier diagnosis, antifungal resistance management, targeted therapies, and improved treatment delivery. Invasive aspergillosis will remain a particularly important area because of its severity and concentration among vulnerable patient populations.

The development of inhaled therapies, novel antifungal mechanisms, rapid diagnostic technologies, and preventive approaches could reshape the competitive landscape. At the same time, expanding access to specialized fungal-disease care in emerging markets will create additional opportunities. Overall, continued pharmaceutical R&D, better diagnostic capabilities, and greater clinical awareness are likely to remain the principal factors supporting long-term market expansion.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com